Stockreport

InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum

InflaRx N.V.  (IFRX) 
Last inflarx n.v. earnings: 8/14 04:05 pm Check Earnings Report
PDF Two out of the first five patients dosed with IFX-1 achieved complete remissionDose escalation warranted by pharmacodynamic analysis and approved by relevant authorities [Read more]